These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 32046737)

  • 1. Is insulin-like growth factor-1 involved in Parkinson's disease development?
    Castilla-Cortázar I; Aguirre GA; Femat-Roldán G; Martín-Estal I; Espinosa L
    J Transl Med; 2020 Feb; 18(1):70. PubMed ID: 32046737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifactorial sleep disturbance in Parkinson's disease.
    Albers JA; Chand P; Anch AM
    Sleep Med; 2017 Jul; 35():41-48. PubMed ID: 28619181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.
    Tong M; Dong M; de la Monte SM
    J Alzheimers Dis; 2009; 16(3):585-99. PubMed ID: 19276553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress and antioxidant therapy in Parkinson's disease.
    Ebadi M; Srinivasan SK; Baxi MD
    Prog Neurobiol; 1996 Jan; 48(1):1-19. PubMed ID: 8830346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
    Cacabelos R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 protects human dopaminergic SH-SY5Y cells from salsolinol-induced toxicity.
    Shavali S; Ren J; Ebadi M
    Neurosci Lett; 2003 Apr; 340(2):79-82. PubMed ID: 12668241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Diagnosis and Indication for Surgical Treatment in Parkinson's Disease].
    Maruo T
    No Shinkei Geka; 2021 Jul; 49(4):750-759. PubMed ID: 34376607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine- Induced Parkinson's Disease in Zebrafish: The Current Applications and Perspectives.
    Abidar S; Hritcu L; Nhiri M
    CNS Neurol Disord Drug Targets; 2023; 22(10):1472-1483. PubMed ID: 36306449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of task-oriented training combined with aerobic training on serum BDNF, GDNF, IGF-1, VEGF, TNF-α, and IL-1β levels in people with Parkinson's disease: A randomized controlled study.
    Soke F; Kocer B; Fidan I; Keskinoglu P; Guclu-Gunduz A
    Exp Gerontol; 2021 Jul; 150():111384. PubMed ID: 33965556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease.
    Mashayekhi F; Mirzajani E; Naji M; Azari M
    J Clin Neurosci; 2010 May; 17(5):623-7. PubMed ID: 20189394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.
    Ayadi AE; Zigmond MJ; Smith AD
    Exp Brain Res; 2016 Jul; 234(7):1863-1873. PubMed ID: 26894890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired brain insulin signalling in Parkinson's disease.
    Bassil F; Delamarre A; Canron MH; Dutheil N; Vital A; Négrier-Leibreich ML; Bezard E; Fernagut PO; Meissner WG
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12760. PubMed ID: 34405431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta.
    Eriksen N; Stark AK; Pakkenberg B
    J Neural Transm Suppl; 2009; (73):203-13. PubMed ID: 20411779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor II prevents oxidative and neuronal damage in cellular and mice models of Parkinson's disease.
    Martín-Montañez E; Valverde N; Ladrón de Guevara-Miranda D; Lara E; Romero-Zerbo YS; Millon C; Boraldi F; Ávila-Gámiz F; Pérez-Cano AM; Garrido-Gil P; Labandeira-Garcia JL; Santin LJ; Pavia J; Garcia-Fernandez M
    Redox Biol; 2021 Oct; 46():102095. PubMed ID: 34418603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of estrogens in Parkinson's disease].
    Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.